New Oral GLP-1 Agonist for Obesity, Type 2 DiabetesHealth care

Caring patient and health is our expertise.|SAN DIEGO, CA – Orforglipron, Eli Lilly's investigational oral daily nonpeptide glucagon-like peptide-1 (GLP-1) agonist that can be taken with or without food, appears comparable with other injectable and oral agents in the class for treating obesity and

Medscape

New Oral GLP-1 Agonist for Obesity, Type 2 Diabetes

New Oral GLP-1 Agonist for Obesity, Type 2 Diabetes

SAN DIEGO, CA – Orforglipron, Eli Lilly's investigational oral daily nonpeptide glucagon-like peptide-1 (GLP-1) agonist that can be taken with or without food, appears comparable with other injectable and oral agents in the class for treating obesity and type 2 diabetes, suggest two new phase 2 studies.